Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
- EligibilityCriteria: Inclusion Criteria:  Participants should be at least 18 years old. Participants should be able to understand the written information and be able to provide informed consent. Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.  Exclusion Criteria:  None applicable - HealthyVolunteers: No - Gender: Male - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients diagnosed with metastatic castration resistant prostate cancer set to receive treatment with Lutetium-177 Prostate Specific Membrane Antigen (Lu-PSMA) as a part of regular clinical care. - SamplingMethod: Non-Probability Sample